Creatine slowed cognitive decline by 30% in early-stage Alzheimer's patients in a 2026 clinical trial. That's the same supplement sitting in your gym bag — and it just got a second job description.
Key Takeaways
- The CABA trial (University of Kansas Medical Center) found 30% slower cognitive decline vs placebo in early Alzheimer's patients
- Mechanism: creatine boosts phosphocreatine stores in neurons, supporting brain energy production
- Creatine is already proven for muscle, bone, and recovery — the brain data adds a new dimension
- This is an independent clinical trial published in Alzheimer's and Dementia: Translational Research — not a brand study
How creatine works in the brain
Creatine isn't just muscle fuel. Your brain is one of the most energy-hungry organs in your body, and it uses the same phosphocreatine/ATP pathway as muscle tissue to fire fast. With age — or with neurodegenerative disease — those brain energy reserves start to drop.
The CABA trial tested creatine monohydrate supplementation in early-stage Alzheimer's patients. The hypothesis: if creatine restores those reserves, it might delay decline. The result was 30% slower cognitive decline compared to placebo. That's not a cure. But for a disease without an effective treatment, it's a signal worth paying attention to.
What this means for people who train
Creatine monohydrate is already the most-researched performance supplement in existence. Dozens of solid studies back its effects on strength, power, recovery, and lean mass.
These brain results don't change the core recommendation for young, healthy athletes. But they add a serious layer for two groups: people training into their 50s and beyond, and anyone with family history of cognitive decline. For those people, creatine isn't just a gym supplement anymore — it's potentially a long-term investment in brain health.
What the research doesn't say yet
The CABA trial was conducted in people already diagnosed with early Alzheimer's — not in healthy adults. Preventive effects in cognitively normal people haven't been shown with the same strength of evidence.
A 2026 PubMed meta-analysis on creatine and cognition in older adults found modest but consistent benefits on short-term memory and processing speed. That's emerging research — not yet strong consensus.
Creatine's safety profile is excellent. Decades of research haven't found meaningful adverse effects at standard doses (3–5g/day) in healthy adults.
Practical takeaways
- Creatine monohydrate is still the most evidence-backed performance supplement. That doesn't change.
- The brain data is promising but early. Worth watching, not overstating.
- For athletes in their 50s+, creatine now has a triple case: muscle, bone, and potentially brain.
- Proven dose: 3–5g/day taken consistently. No cycling needed.
- This is an independent clinical trial, not a supplement brand study — which makes the signal more credible.